Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs CRSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRSP Captures Overall Composite Edge (48.6 HOLD vs 51.6 HOLD), While EDIT Leads 4–2 on Growth & Valuation Pillars

CRSP Overall Winner 6-Pillar Tally: EDIT 4 – 2 CRSP Matrix Metrics: EDIT 3 – 7 CRSP

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (48.6/100 HOLD vs. 51.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Growth & Scale), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus CRSP at $40.61 (23.4x Forward P/E, -2058.6% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -167.0% operating margin) and revenue trajectory (+1325.1% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs CRSP
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $2.52 · SMA50: $2.61
CRSP NASDAQ Head-to-Head Winner
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80

6-Pillar Scorecard Institutional Category Breakdown (EDIT 4 – 2 CRSP)

Columns: Metric · EDIT · CRSP
1. Valuation Multiples CRSP
Forward P/E N/M 23.4x
Trailing P/E N/M 23.4x
PEG Ratio N/M N/M
EV / Revenue 5.2x N/M
2. Growth & Scale CRSP
Revenue Growth (YoY) +37.4% +1325.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M $25M
Market Cap $336.5M $4.1B
3. Profitability & Quality EDIT
Gross Margin -73.3% N/A
Operating Margin -167.0% -2058.6%
Net Profit Margin -144.9% 0.0%
Return on Equity (ROE) -147.4% -25.6%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$110M -$378M
Cash Flow Margin N/A N/A
Net Cash / Leverage $79M Net Cash $588M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 95.8% (38th %ile) 97.8% (52nd %ile)
Put/Call OI Skew 0.29x (Call-Skewed) 0.65x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (3) vs CRSP (7)
Institutional Metric EDIT CRSP Criterion Row Edge
Market Capitalization
Scale
$336.5M $4.1B Larger Scale CRSP
Trailing P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+37.4% +1325.1% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-167.0% -2058.6% Higher Margin EDIT
Net Profit Margin
Profitability
-144.9% 0.0% Higher Margin CRSP
Return on Equity (ROE)
Capital Efficiency
-147.4% -25.6% Higher ROE CRSP
52-Week Range Position
Momentum
11% ($2–$4) 1% ($40–$63) Stronger Trend EDIT
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 1.85β · 60% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$50M $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) -$378M ($588M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRSP +1.4 pp
EDIT: -18.94% · CRSP: -17.54%
3M Horizon CRSP +10.52 pp
EDIT: -33.85% · CRSP: -23.33%
6M Horizon CRSP +8.33 pp
EDIT: -24.7% · CRSP: -16.37%
1Y Horizon CRSP +4.46 pp
EDIT: -25.0% · CRSP: -20.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EDIT Revenue CRSP Revenue EDIT Op. Margin CRSP Op. Margin Margin Leader
FY2018 $30M $0M -356.1% -5087.8% EDIT
FY2019 $20M $290M -686.4% 16.1% CRSP
FY2020 $90M $0M -148.6% -49295.5% EDIT
FY2021 $30M $910M -756.1% 40.8% CRSP
FY2022 $20M $0M -1146.3% -56190.4% EDIT
FY2023 $80M $370M -216.6% -60.0% CRSP
FY2024 $30M $40M -777.2% -1250.4% EDIT
FY2025 $40M $0M -394.9% -18933.6% EDIT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EDIT vs CRSP Key Questions & Quantitative Answers

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (48.6/100 HOLD vs. 51.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Growth & Scale), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus CRSP at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -167.0% operating margin) and revenue trajectory (+1325.1% vs. +37.4% YoY). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.

CRSP screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus CRSP (-25.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.